ReviewDrug safety2020

Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.

Vijayabhaskar Veeravalli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.